Exploring the readiness of the Irish healthcare system to adopt advanced therapies: a scoping review protocol.
Isabella DevineClarice O'BrienDavid MocklerCormac KennedyGerard HughesMartina HennessyPublished in: Regenerative medicine (2024)
Aim: Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. Materials & methods: Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted. Results: Findings will be presented via narrative summary, graphical and tabular formats. Discussion: Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.
Keyphrases
- meta analyses
- systematic review
- randomized controlled trial
- healthcare
- induced apoptosis
- endothelial cells
- general practice
- electronic health record
- public health
- primary care
- cell cycle arrest
- gene expression
- genome wide
- adverse drug
- white matter
- endoplasmic reticulum stress
- induced pluripotent stem cells
- pluripotent stem cells
- clinical practice
- stem cells
- signaling pathway
- cell death
- mesenchymal stem cells
- bone marrow
- oxidative stress
- combination therapy
- replacement therapy
- pi k akt
- cell therapy